InsiderTrades

Form 4 for OKUR OnKure Therapeutics, Inc.

Accepted 2025-05-19 00:00:00 ET · period of report 2025-05-15 · accession 0000950170-25-074459 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
I 2025-05-19 2025-05-15 OKUR ACORN CAPITAL ADVISORS GP, LLC 10% P - Purchase $1.85 +1.13M 1.13M New +$2.09M
2025-05-19 2025-05-15 OKUR ACORN CAPITAL ADVISORS GP, LLC 10% P - Purchase $1.85 +270.3K 1.71M +19% +$500.0K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-05-15 P A 1,129,730 $1.85 1,129,730 I — — (F2) Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
2 Common Common Stock 2025-05-15 P A 270,270 $1.85 1,709,944 D By Acorn Bioventures 2, L.P. — — (F1) Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.